Antithrombotic Strategies After Complex Percutaneous Coronary Intervention
Key result
Antithrombotic therapy after complex PCI requires balancing ischemic and bleeding risks over procedural complexity alone.
Figures
Why the study?
Patients undergoing complex PCI frequently carry high bleeding risk alongside high ischemic risk, making the selection of antithrombotic regimens challenging as guidelines emphasize balancing both risks.
Key Points
- The aim is to explore antithrombotic strategies post-complex PCI, focusing on ischemic and bleeding risk balance.
- Reviewed contemporary evidence and guideline recommendations
- Analyzed clinical considerations for antithrombotic therapy
- Focused on diverse complex PCI scenarios such as bifurcation lesions and chronic total occlusions.
- Antithrombotic therapy is crucial in reducing the risk of ischemic events post-PCI.
- Patients undergoing complex PCI face significant bleeding risks requiring careful regimen selection.
- Recent guidelines emphasize a risk balance approach instead of focusing solely on procedural complexity.
Structured PICO
P
Population
Patients undergoing complex percutaneous coronary intervention (PCI), including left main disease, bifurcation lesions requiring two-stent strategies, chronic total occlusions, long stent lengths, severe calcification requiring atherectomy, and multivessel revascularization
I
Intervention
Antithrombotic therapy (antiplatelet and anticoagulant agents)
Antithrombotic therapy after complex PCI should be individualized by balancing ischemic and bleeding risks rather than relying solely on procedural complexity.
Implication
Tailored antithrombotic regimens balancing ischemic and bleeding risks should guide post-complex PCI care; reinforces guideline-driven individualization over anatomy alone.
Abstract
Complex percutaneous coronary intervention (PCI) represents a growing proportion of contemporary coronary revascularization, driven by aging populations, increasing comorbidity burden, and advances in interventional techniques. Complex PCI encompasses a spectrum of anatomically and procedurally challenging lesions, including left main disease, bifurcation lesions requiring two-stent strategies, chronic total occlusions, long stent lengths, severe calcification requiring atherectomy, and multivessel revascularization. Antithrombotic therapy, comprising antiplatelet and anticoagulant agents, is essential for preventing stent thrombosis and other ischemic events in both the early and long-term phases after PCI. While antithrombotic therapy mitigates ischemic risks associated with complex PCI, these patients frequently carry a high bleeding risk, thus making the choice of antithrombotic regimen challenging. Recent guideline recommendations emphasize balancing ischemic and bleeding risks rather than relying solely on procedural complexity. This review synthesizes contemporary evidence, guideline recommendations, and clinical considerations for antithrombotic therapy after complex PCI.
J Clin Med · review. After complex PCI, bleeding and ischemic risk, not anatomy, should drive antithrombotics. Antithrombotic Strategies After Complex Percutaneous Coronary Intervention What makes PCI complex: Left main, Two-stent bifurcation, Chronic total occlusion, Severe calcification. Often both risks in one patient: Ischemic risk vs Bleeding risk. Choosing the antithrombotic regimen: Complex PCI → Weigh ischemic risk → Weigh bleeding risk → Tailored regimen. Bottom line: Guidelines favour individualized regimens weighing both risks over procedural complexity alone.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Ueki et al. (2026) conducted a review in Complex percutaneous coronary intervention (PCI). Antithrombotic therapy was evaluated. Antithrombotic therapy after complex PCI requires balancing ischemic and bleeding risks rather than relying solely on procedural complexity.